Innovative Therapies Centers of Excellence Act of 2025
Summary
HR2623 mandates the VA to establish five innovative therapies centers focused on advanced treatments including psychedelics. The bill is in early committee stage with 27 cosponsors and no appropriated funding yet. The tickers CMPS, GHRS, ATAI, and DRUG have rallied significantly over 30 days (17% to 52%) on the Executive Order and legislative signal, but remain well below 52-week highs.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR2623 is a policy authorization with zero allocated funding — the market is pricing in future appropriations that do not yet exist.
- 2.All four psychedelic tickers have rallied 17-52% in 30 days but have 7-day declines of 0.2-12.4%, indicating profit-taking after the Executive Order pop.
- 3.The VA is the ideal first customer for psychedelic therapies due to the high veteran PTSD/depression prevalence, but commercialization is 2-4 years away.
- 4.Companion bill S4031 increases passage probability, but the authorization-appropriation gap remains the critical risk factor.
Market Implications
The four pure-play psychedelic developers (CMPS $8.39, GHRS $19.27, ATAI $4.17, DRUG $88.97) have already priced in significant legislative optimism with 30-day gains of 17-52%. The 7-day pullback (CMPS -12.4%, ATAI -9.9%) suggests the market is repricing the probability and timeline of actual appropriations. These stocks remain highly speculative — they are all below their 52-week highs (CMPS: 82% of high, GHRS: 78%, ATAI: 62%, DRUG: 72%) and face binary risk from the appropriations process. Investors should monitor the House VA Committee markup schedule and any FY2027 VA appropriations language. The structural bull case is intact — the VA is the ideal early adopter — but near-term momentum has stalled as the legislative reality (zero funding, early stage) sets in.
Full Analysis
HR2623, the 'Innovative Therapies Centers of Excellence Act of 2025,' was introduced in the House on April 3, 2025, by Rep. Correa (D-CA) and referred to the House Veterans' Affairs Committee. The bill requires the VA to designate at least five medical facilities as innovative therapies centers to research and deliver advanced treatments, explicitly including psychedelic-based therapies for conditions like PTSD and depression. A companion bill (S4031) has been introduced in the Senate, and an Executive Order has separately directed acceleration of psychedelic treatment reviews.
Crucially, the bill authorizes the establishment of these centers but explicitly states operations are 'subject to the availability of appropriations.' This is an authorization bill — it sets policy direction and creates a legal framework, but allocates zero dollars. Actual funding requires a separate appropriations bill. The bill has 27 cosponsors (bipartisan: Correa, Bergman, Crenshaw, Khanna, Luttrell) but remains in early committee stage with only four actions to date.
The psychedelic therapy sector has four publicly traded pure-plays: CMPS ($8.39), GHRS ($19.27), ATAI ($4.17), and DRUG ($88.97). All four have rallied sharply over the past 30 days (CMPS +51.7%, GHRS +37%, ATAI +17.8%, DRUG +21.9%) following the Executive Order announcement. However, the 7-day trend is negative (CMPS -12.4%, GHRS -4.9%, ATAI -9.9%, DRUG -0.2%), suggesting the initial Executive Order pop is fading as investors recognize the authorization-appropriation gap.
The structural winners remain the pure-play psychedelic developers because the VA represents the single largest concentrated patient population for PTSD/depression (over 1 million veterans diagnosed). Unlike the commercial insurance path (requiring lengthy reimbursement approvals), a VA center of excellence can directly procure and administer therapies. However, the legislative timeline is lengthy: the bill must pass committee, pass the House, pass the Senate (companion S4031 helps), and then secure an appropriations rider. This is a multi-year catalyst, not an imminent revenue event.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Bill mandates the VA to designate at least five medical facilities as 'innovative therapies centers of excellence' to research and deliver advanced treatments, including psychedelic-based therapies, subject to future appropriations. An Executive Order accelerating psychedelic treatments provides policy tailwind.
Who must act
Secretary of Veterans Affairs, under the Under Secretary for Health, must designate facilities and establish centers upon appropriation.
What happens
Creates a federal procurement pathway for psychedelic drug development contracts and clinical trial services targeting PTSD and depression in the veteran population (the single largest eligible cohort for such treatments).
Stock impact
CMPS is the leading pure-play developer of psilocybin therapy (COMP360), currently in Phase 3 for treatment-resistant depression. VA adoption would open a direct government procurement channel for its therapy, drastically shortening commercial adoption timelines and reducing dependence on private insurance/reimbursement.
What the bill does
Same as above — bill mandates VA innovation centers that integrate psychedelic therapies; Executive Order accelerates regulatory pathway.
Who must act
Secretary of Veterans Affairs
What happens
Creates federal demand signal for mecamylamine-based therapies (GHRS's lead candidate, GH001) for treatment-resistant depression, with VA as a first-mover adopter rather than waiting for commercial insurance coverage.
Stock impact
GHRS is developing intranasal mecamylamine for psychiatric disorders. VA centers of excellence would provide a clinical deployment venue for its lead candidate, reducing time-to-revenue and providing federal reimbursement clarity.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Mental Health Research Accelerator Act of 2025
Veterans Health Administration Novel Therapeutics Preparedness Act
Freedom to Heal Act of 2025
Freedom to Heal Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Restoring Reciprocity in Government Procurement
This Presidential Memorandum directs the Office of Management and Budget, the U.S. Trade Representative, and other federal agencies to identify and remove Canadian-origin items from federal civil procurement where possible, citing Canada's 'Buy Canadian' policies as discriminatory. It also requires agencies to be notified of domestic alternatives and mandates ongoing monitoring of Canada's procurement practices, with provisions for restoring access if Canada changes its policies.
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →